Pharmaceutical formulation for use in spinal fusion
US10589001B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Sep 7, 2011 |
| Grant date | Mar 17, 2020 |
| Priority date | — |
| Expiry date | Apr 3, 2034 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61L2430/38
- WIPO fieldMedical technology
- WIPO sectorInstruments
Abstract
A pharmaceutical formulation for use in a spinal fusion method, comprising a composition for forming a matrix, a kit comprising the composition, a pharmaceutical product obtainable from the pharmaceutical formulation, and an interbody spinal fusion cage containing the pharmaceutical formulation or the pharmaceutical product are described herein. The composition comprises at least a first matrix material precursor component and a second matrix material precursor component that are able to crosslink to form the matrix under appropriate conditions, a bioactive factor that is biologically active for stimulating bone formation between two vertebrae and for effecting or supporting spinal fusion. The bioactive factor is PTH, optionally a PTH fusion peptide. The bioactive factor is releasably incorporated in the matrix upon crosslinking of the matrix material precursor components.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.